WO2009137859A1 - Composés pour le traitement du syndrome métabolique et de la résistance à l'insuline - Google Patents

Composés pour le traitement du syndrome métabolique et de la résistance à l'insuline Download PDF

Info

Publication number
WO2009137859A1
WO2009137859A1 PCT/AT2009/000200 AT2009000200W WO2009137859A1 WO 2009137859 A1 WO2009137859 A1 WO 2009137859A1 AT 2009000200 W AT2009000200 W AT 2009000200W WO 2009137859 A1 WO2009137859 A1 WO 2009137859A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
extract
ellagic acid
compound
tms
Prior art date
Application number
PCT/AT2009/000200
Other languages
English (en)
Inventor
Alois Jungbauer
Original Assignee
Alois Jungbauer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alois Jungbauer filed Critical Alois Jungbauer
Priority to EP09745281A priority Critical patent/EP2303252A1/fr
Publication of WO2009137859A1 publication Critical patent/WO2009137859A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to natural compounds suitable for the treatment of insulin related metabolic diseases.
  • Metabolic Syndrome also known as the Insuline Resistance Syndrome
  • the symptoms of Metabolic Syndrome are related to lipid and carbohydrate metabolism and include obesity, elevated triglycerides, low levels of high density lipoproteins, increased blood pressure or hypertension and increased glucose levels, but also symptoms of inflammation.
  • the individual symptoms associated with the Metabolic Syndrome are treated separately (e.g. diuretics and ACE inhibitors for hypertension, statins to decrease cholesterol levels or glitazones to treat diabetes) .
  • the problem is compounded when multiple drugs are necessary to control multiple risk factors. For example, once type 2 diabetes develops in patients with the Metabolic Syndrome, patients often require 10 or more drugs for treatment.
  • TZDs thiazolidinediones
  • These drugs act by agonizing the nuclear receptor PPAR-gamma, which is predominantly expressed in adipose tissue, but also occurs in other tissues (WO 2005/027661; CA 2 526 589) .
  • TZDs reduce the secretion of unesterified fatty acids and adipokines such as tumour- necrosis factor-alpha (TNF-alpha) , other inflammatory cytokines, resistin and plasminogen-activator inhibitor 1 (PAIl) ; they also enhance adipose-tissue release of adiponectin.
  • TNF-alpha tumour- necrosis factor-alpha
  • PAIl plasminogen-activator inhibitor 1
  • Insulin resistance is a key factor in development of the Metabolic Syndrome.
  • This syndrome is the coexistence of hy- perglycaemia, hypertension, dyslipidemia and obesity. Therefore cardiovascular diseases such as coronary heart diseases and stroke are more prevalent among patients with Metabolic Syndrome.
  • a classification of insulin resistance and the Insulin Resistance Syndrome (Metabolic Syndrome) is present in the ACE- Position-Statements (Endocr. Pract. 2003; 9 (No. 3) 240-252) which shall be used herein. Although these diseases share a common origin, yet should be strictly kept apart as different symptoms and disease progression occur.
  • the PPAR-gamma is a class II nuclear receptor that forms a heterodimer with the retinoid X-receptor (RXR) and binds to specific regions on the DNA of target genes. Expression of target genes is increased or decreased, depending on the gene.
  • PPAR- gamma is composed of 6 structural regions in 4 functional domains.
  • the A/B region forms the ligand-independent transactiva- tion domain which can be covalently modified by phosphorylation.
  • the C region the DNA-binding domain of the receptor can be targeted to the PPAR-gamma response element (PPRE) , a specific sequence of nucleotides within the regulatory region of responsive genes.
  • PPRE PPAR-gamma response element
  • the E/F region contains the ligand binding domain and the co-activator/co-repressor-binding surface. Binding of agonists leads to conformational changes of the receptor and to its activation.
  • the activated receptor heterodimerizes with RXR and this heterodimer binds to PPRE through the DNA-binding domain.
  • Natural ligands of the PPAR-gamma receptor are fatty acids such as lauric acid, petroselenic acid, linolenic acid, linoleic acid and arachidonic acid, fatty acid metabolites like 15-deoxy- delta 12, 14-prostaglandin J2.
  • the synthetic ligands comprise the group of thiazolidinedions (Troglitazone, Rosiglitazone, Piogli- tazone) , the non-thiazolidinediones (e.g. GW1929, GW7845) and the non-steroidal anti-inflammatory drugs (e.g. flufenamic acid, fenoprofen) .
  • natural ligands for the PPAR-gamma are polyunsaturated fatty acids and eicosanoids .
  • This receptor is expressed in many tissues like adipose tissue, heart, muscle, colon, kidney, liver and is mainly responsible for adipocyte differentiation and energy storage.
  • PPAR-gamma may also play a critical role in the pathogenesis of atherosclerosis through in- fluencing the circulating lipid and glucose level or directly- through modulating of macrophage functions. It was recently discovered, that platelets also contain the transcription factor PPAR-gamma and the role of PPAR ligands on prevention of unwanted platelet activation and chronic inflammatory diseases has to be proven.
  • PPAR-gamma downregulates TNF-alpha, leptin, IL-6, plasminogen activator inhibitor-1 (PAI-I) , resistin, 11-beta- hydroxysteroid dehydrogenase type-1 (11-beta-HSD-l) .
  • PAI-I plasminogen activator inhibitor-1
  • resistin 11-beta- hydroxysteroid dehydrogenase type-1
  • WO 2005/053724 mentions non-aqueous extracts of Astragalus membranaceus which influence PPAR-gamma.
  • Compounds found in these extracts are for example calycosin, formononetin, gen- istein, afromorsin, biochanin A, coumestrol, odoratin and daidzein.
  • PPAR-gamma mediated diseases which can be treated with the extracts are dyslipidaemia, atherosclerosis, coronary heart disease, obesity and colon cancer.
  • WO 2005/027661 describes catechines, which are obtainable from green tea, as activating ligands of PPAR-gamma.
  • the ligands mentioned therein in particular glitazone, rosiglitazone, ciglitazone and pioglitazone, fall under the group of TZDs.
  • TZDs for example troglitazone are mentioned in the US 2006/0030597 Al.
  • CA 2 526 589 Al describes ligands of PPAR-gamma, in particular glabrene, glabridine, glabrol and their derivatives, and glitazones. These compounds are mentioned in connection with the multiple risk factor syndrome, another name of the Metabolic Syndrome, which is related to insulin resistance and can be treated with PPAR-gamma ligands. Also described is a licorice extract for the treatment of Metabolic Syndrome.
  • EP 1 350 516 Bl claims a hydrophobic licorice extract, and extracts from turmeric, clove and cinnamon for the use of treating Metabolic Syndrome as well as associated diseases like visceral obesity and diabetes mellitus .
  • the activity of the extracts is measured in reference to troglitazone and pioglitazone.
  • JP 2005/097216 mentions dehydrodieugenol A and B, magnolol, oleanic acid and betulic acid as PPAR-gamma ligands that are useful for preventing or ameliorating Metabolic Syndrome.
  • the EP 1481669 Al describes polyhydroxy phenol and polyphenols such as ellagic acid for the inhibition of P-selectin.
  • the WO 2006/022502 describes compounds with diphenoyl structure for a treatment of immune diseases.
  • the EP 1312374 describes the use of an extract from evening primrose to relieve symptoms of diabetes mellitus.
  • the extract may contain ellagic acid.
  • the WO 2007/038768 describes a method for preventing or treating metabolic syndrome using a grape extract as dietary supplement. According to this document the absence of epicate- chin-gallate or only a small amount thereof in addition to a high amount of low molecular weight compounds is responsible for increased vasodilatation which is believed to be responsible for a drop in blood pressure in individuals with metabolic syndrome.
  • the present invention provides a compound comprising an ellagic acid moiety, such as ellagic acid itself, el- lagitannins and ellagic acid glycosides - as well as plant extracts comprising the same, for the treatment or prevention of Metabolic Syndrome or non-diabetic insulin resistance. Also described is the method of treating or preventing Metabolic Syndrome or non-diabetic insulin resistance with the compound comprising the ellagic acid moiety or the extract. In addition, the invention also relates to the use of the invention and extracts for the manufacture of a pharmaceutical preparation for the treatment or prevention of said diseases or conditions.
  • an ellagic acid moiety such as ellagic acid itself, el- lagitannins and ellagic acid glycosides - as well as plant extracts comprising the same.
  • the method of treating or preventing Metabolic Syndrome or non-diabetic insulin resistance with the compound comprising the ellagic acid moiety or the extract.
  • the invention also relates to
  • the Metabolic Syndrome also termed "Insulin Resistance Syndrome” is a non-diabetic accumulation of risk factors, which can lead to the development of diabetes but it is not identical with diabetes.
  • the Metabolic Syndrome i.e. the Insulin Resistance Syndrome
  • WHO World Health Organization
  • Diabetes mellitus Venous plasma glucose concentration m ⁇ ol/1 mg/dL fasting or ⁇ 7.0 ⁇ 126
  • Insulin resistance is by itself characterized by an insufficient function of insulin, it can give rise to compensatuary hy- perinsulinemia (as a precursor to the Metabolic Syndrome) or result in an inadequate insulin response (as a precursor to diabetes) .
  • insulin resistance, the Metabolic Syndrome and diabetes type 2 are conditions which are defined to be mutually exclusive (ACE Position Statement, Endocr Pract. 9(3), 2003: 240-252) .
  • the present invention provides the use of the inventive compounds and pharmaceutical compositions for the treatment or prevention of the Metabolic Syndrome and insulin resistance - in particular non-diabetic - but also contemplates their use for the treatment of diabetes, in particular type 2 diabetes.
  • the abnormalities related to elevated triglycerides, HDL cholesterol values and increased blood pressure are characteris ⁇ tics of the Metabolic Syndrome.
  • Drugs for the treatment of Metabolic Syndrome are required to enhance insulin sensitivity, as well as the other manifestations of the insulin resistance syn ⁇ drome. This action was surprisingly found in the plants and com ⁇ pounds of the present invention which interact with the PPAR- gamma.
  • PPAR-gamma interaction has a beneficial effect on insulin sensitivity but also on the lipid profile, blood pressure, haemostasis and can significantly reduce the risk of cardiovascular disease associated with Metabolic Syndrome (Walcher et al., Diabetes and Vascular Res. 2004 (2): 76-81) .
  • impaired transactivation which has been described in the frequent genetic polymorphism Alal2Pro of the PPAR-gamma gene, leads to higher insulin sensitivity (but lower postprandial hypertriglyceridemia) , and a haplotype for which higher transcriptional activity is postulated has an increased risk for Metabolic Syndrome. Therefore, a non-linear activity- effect curve has been proposed for PPAR-gamma activity, with small increases in activity having opposite effects than stronger activation by ligands .
  • the known antidiabetic effect of grape seed extracts and the lower cardiovascular disease (CVD) incidence due to red wine consumption is well documented.
  • the present invention provides the identification of ellagic acid (2, 3, 7, 8-tetrahydroxy- [1] Benzopyrano [5, 4, 3-cde] [1] benzopyrano-5, 10-dione) and its associated ellagitannins found in plants with potential health benefit through PPAR-gamma binding and therefore responsible for transactivation and/or repression.
  • Prevention in the sense of the present invention should not be construed in an absolute sense in that the target diseases and conditions are with 100% certainty prevented but in a relative sense, i.e. as decreasing the risk of developing said diseases or conditions. Accordingly, the compounds are used for prophylactic administration.
  • ellagic acid moiety is to be understood as the molecular backbone of ellagic acid not counting its hydrogen atoms.
  • a compound with said moiety is thus ellagic acid itself or a derivative wherein hydrogens are substituted.
  • These derivatives include esters, ethers or amides of ellagic acid, in particular glycosides, glyco esters of ellagic acid such as ellagic acid-galactoside or -glucoside.
  • Ellagic acid naturally forms intermolecular esters (lactone) that can be hydrolized, in particular upon derivatisation, such as during ellagitannin formation.
  • the ellagic acid moiety may therefore be one of the following:
  • Ellagic acid is found in plants in its free form (cyclic intramolecular ester form, i.e. lactone form) but predominantly as complex ester (ellagitannins) or non-tannic glycosidic forms
  • An ellagitannin may contain one, two, three or more "ellagic acid moieties", in particular hexahydroxydiphenic acid of formula 3 or the intermediate of formula 2.
  • the carboxylic acid groups may be subject of derivatisation or substitution forming esters, or amines.
  • An ellagitannin may further be an ester of tannic or gallic acid, sugar units, preferably glucose, and/or further hydroxydipehnic acids.
  • the ellagitannin derivative of ellagic acid is of the following structure
  • the inventive compound is hydrolyzable to ellagic acid (or convertable to ellagic acid by hydrolysis) , such as ellagitannins which contain one or more hexahydroxydiphenic acid moieties (such as of formula 3) esterified to a polyol, usually glucose.
  • ellagitannins which contain one or more hexahydroxydiphenic acid moieties (such as of formula 3) esterified to a polyol, usually glucose.
  • Hydrolysis of ellagitannins with acids or bases yields hexahydroxydiphenic acid which spontaneosly lactonizes to el- lagic acid of formula 1.
  • the phenolic hy- droxygroups may be substituted by ether, ester or amide groups.
  • Hydrolyis may be effected by strong or weak acids or bases, e.g. at a pH of below 4, 3, 2, or 1 or above 10, 11, 12 or 13. In particular hydrolysis can occur in human gastric conditions.
  • the present invention provides a plant extract comprising the inventive compounds for the treatment or prevention of metabolic syndrome or non-diabetic insulin resistance, preferably the compound is enriched in said extract.
  • a plant extract comprising the compound as described above, in particular ellagic acid, wherein the compound is specifically enriched by at least 50%, preferably by at least 75% or even more preferred by a factor of at least 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30, 40, 50, 60, 70, 80, 100, 120, 140, 160, 180, 200, 250, 300, 400, or at least 500.
  • An extract of the present invention may be a solid or fluid extract.
  • the "specific enrichment” refers to the increased concentration of the inventive compounds, ellagitannins, ellagic acid and/or ellagic acid glycosides, with reference to all solid plant constituents of an untreated plant or plant portion (such as fruits) from which the extract is derived.
  • the extract comprises at least 1%, 2%, 3%, 4%, 5%, 8%, 10%, 15%, 20%, 25%, 30%, 35%, 40% or at least 50% (w/w of the solid mass) of the inventive compounds.
  • the extract is an extract of berry, fruit and nut species or of oak, including oak wood.
  • the extract may be of plants rich in ellagic acid or ellagitannins such as berry, fruit, and nut species. They have been detected in berries of the genus Rubus (raspberry, blackberry, cloudberry, arctic bramble) and the genus Fragaria (strawberry) , pomegranate, walnuts, and some other nuts, and oak-aged wines (Koponen et al., J. Ag- ric. Food Chem. 2007, 55, 1612-1619) .
  • minor amounts of ellagic acid are usually present as free and glycosylated forms.
  • the extract may also benefit from more than one plant, e.g. extraction of more than one berry species or a berry and oak extraction.
  • the extract is of grapes, preferably of grape seeds and/or skin. Grape constituents including ellagic acid and its derivatives are also found in red wine, which can also be used for obtaining the extract.
  • red wine is also rich in tannins found in oak providing a further increase of the ellagitannin and ellagic acid concentration.
  • red wine consumption has been made responsible for the beneficial effect on cardiovascular diseases and inflammation. This has been mainly referred to resveratrol in the past. Due to the low abundance of resveratrol in red wine and medium potency to many hormone receptors the beneficial effects was surprisingly found due to the PPAR-gamma activity.
  • ligand binding of different wines was studied and neat wine compounds and extracts assayed for peroxisome pro- liferators activated receptor gamma binding in a competitive ligand binding assay.
  • Grape skin derived compounds like resveratrol, apigenin, piceatannol, kaempferol and myricetin showed only medium binding affinity in the ⁇ M range.
  • GCMS ellagic acid was identified and assessed in the ligand binding assay as strong binder with a IC50 of 5.7xlO "7 M.
  • the extract is a tannin extract. Tannin fraction of diverse plants are especially rich in ellagitannins and yield a high amount of ellagic acid.
  • the extract is a red wine or a red wine concentrate, preferably of oak containers aged wine.
  • Red wines are natural extracts of grapes, including grape skin or seeds which are rich in ellagic acid containing moieties. A further enrichment occurs due to contact with oak, such as by storage in oak containers, barrels or caskets.
  • the present invention provides a pharmaceutical composition of the extract or compound.
  • the composition may be in solid form, preferably a powder, tablet or capsule, or fluid.
  • the pharmaceutical preparation according to the invention comprises a pharmaceutical carrier or additive.
  • a pharmaceutical carrier includes wetting, emulsifying, or pH buffering agents or vehicles with which the pharmaceutical preparation can be contained in or administered. Examples are oils, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the agents of the pharmaceutical preparation are formulated in solid form, including salt forms, or fluid form.
  • Pharmaceutically ac- ceptable salts include those formed with anions ; such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric, butyric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
  • the preparation is an oral preparation, in particular preferred in form of a juice or tablet.
  • the extracts, juices or compounds can be dried and formulated into tablets and administered orally.
  • the preparations can be formulated in the form of tablets, capsules, cachets, gelcaps, solutions, suspensions, and the like.
  • Tablets or capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose) ; fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrants (e.g., potato starch or sodium starch glycolate) ; or wetting agents (e.g., sodium lauryl sulphate) .
  • binding agents e.g., pregelatinized maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc, or silica
  • disintegrants e.g., potato
  • Liquid preparations for oral administration may take the form of, but are not limited to, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); nonaqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl- p-hydroxybenzoates or sorbic acid) .
  • the preparations may also contain buffer salts, flavoring, coloring, and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated for slow release, controlled release, or sustained release of a prophylactic or therapeutic agent (s) .
  • Fig. 1 Binding analysis of twelve different wines. The relative binding affinity (RBA) was calculated by relating the binding affinities with the maximum binding affinity of rosiglitazone.
  • Fig. 2 Fractionation wine W6: (A) HPLC run and (B) ligand binding assay from the fractions. 4xl00 ⁇ l were injected, 1 ml fractions were collected (B: x-axis: fraction number), solvent was evaporated and the residues were dissolved in 100 ⁇ l DMSO and used for the ligand binding assay.
  • RBA relative binding affinity
  • Fig. 3 Logistic dose response curves of oak tannin (tannin Q) and grape tannin extracts.
  • Fig. 4 Logistic dose response curves from ellagic acid, epigal- locatechingallate and epicatechingallate and the synthetic PPAR- gamma ligand rosiglitazone for the determination of the inhibitory concentrations (IC 50 values) .
  • Fig. 5 GCMS analysis of wine W ⁇ (A), oak tannin extract (B) and grape tannin extract (C) .
  • PPAR-gamma peroxisome prolifera- tors-activated receptor-gamma
  • the grape extract Tannin Grape Erbsl ⁇ h, Geisenheim, Germany
  • the oak extract Tannin Q Sulfometa, Krems, Austria
  • the extract were made using a 20% ethanolic solution.
  • Analytical -HPLC system for sample fractionation All HPLC runs were performed with an Agilent 1100 HPLC system (Waldbronn, Germany) . The fractionation was achieved by RP-HPLC using a C 18 (2) Luna 3 ⁇ m column (Phenomenex, Torrance CA, USA) . Eluent A was de- ionized and 0.22 ⁇ m filtered water, supplemented with 5% ace- tonitrile and 0.1% TFA, eluant B was acetonitrile supplemented with 0.1% TFA.
  • Preparative HPLC system for ligand identification Isolation and identification of the single compounds was achieved with a preparative Agilent 1200 HPLC system. A reversed phase column C18 (2), 250x20.21mm column volume and 15 ⁇ m particle diameter (Phenomenex, Torrance CA, USA) was used. Buffer and gradient conditions were the same as for the analytical separation. The flow rate was 26.5 mL/min and the fractions were collected every 2 min. They were evaporated and .the residues dissolved in etha- nol and used for ligand binding assay and GCMS analysis, respectively.
  • PPAR-LBD is added to a fluorescent PPAR ligand (FluormoneTM PPAR Green) to form a PPAR - LBD/FluormoneTM PPAR Green complex resulting in a high polarization value.
  • Competitors displace the fluorescent FluormoneTM PPAR Green ligand from the ligand binding domain, resulting in a low polarization value.
  • Noncompetitors will not displace the fluorescent ligand from the complex, so the polarization value remains high.
  • the shift in polarization value is used to determine relative affinity of test compounds for the PPAR-LBD.
  • GC-MS was performed using a GC 6890N / MSD 5973B instrument (Agilent Technologies) .
  • BSTFA Bistrimethylsilyltri-fluoroacetamide
  • Separation of the compounds was achieved on fused silica HP-5ms (30m, 0.25mm, 25 ⁇ m) column using helium as carrier gas, a helium column flow of 0.9ml /min, an oven programme starting with 100 0 C (5 min), then 10°C/min to 280°C (20 min), and an auxiliary temperature programme starting at 24O 0 C (18min), then 10°C/min to 280 0 C (14min) .
  • Inlet was operated in split mode (25:1) at 280°C. Ionization was performed in EI mode at 70 eV, 230 0 C, and 1.5*10 ⁇ 5 Torr. Data acquisition and processing were performed using the MSDChem software package (Agilent Technologies) . Furthermore, the mass spectral library NIST 2002 (National Institute of Standards and Technology, USA) and its implemented search routine were employed for identifying the multitude of peaks in the obtained total ion chromatograms .
  • Rosiglitazone is a known synthetic strong PPAR-gamma binder and is used as a reference substance to compare extracts and wines.
  • the equivalent concentration of the wine samples is calculated by dividing the potency of rosiglitazone in ⁇ mol/L by the potency of the wine samples in L/L (equation.2) :
  • Table 1 lists an overview of their types and production qualities.
  • Table 2B gives theis PPAR-gamma binding activity as rosiglitazone equivalents.
  • Table IB Description of the wines - chemical aspects Compound/Analysis Wl W2 W3 W4 W5 W6 W7 W8 W9 WlO WIl W12
  • Fructose (g/L) 4.2 6.1 0.5 0.5 n.d. 0.1 n.d. 0.1 0.1 n.d. 0.1 n.d.
  • Lactic acid (g/L) 1.0 1.1 1.9 2.5 3.1 1.8 2.7 1.9 1.8 1.5 1.8 1.5
  • Fraction 15 is also the most coloured part of the linear gradient.
  • Anthocyanins, especially cyanidin were mentioned to regulate adipocyte function. Therefore, malvidin, cyanidin and the glucosides were evaluated as the most abundant wine anthocyanins for PPAR-gamma binding. Malvidin and especially cyanidin aglycon showed high binding affinity (Table 3) . Malvidin-O- glucoside neat compound has the same retention time as the dominant peak in fraction 15, but with no binding affinity in the ligand binding assay. One possible reason could be a structure change due to oxidation or cleavage and also the presence of other potent ligands in this fraction.
  • Fraction 12 Protocatechuic acid, syringic acid, gallic acid, ferulic acid, affeic acid, epi- We could identify ellagic acid in fraction 15 and quercetin in fraction 16 as very potent ligands and therefore responsible for the high activity of these fractions.
  • GCMS analysis of wine W6 was performed to determine potential ligands. Beside known grape derived compounds oak polyphenols, in particular ellagic acid, were identified.
  • the neat compounds were tested in the ligand binding assay. Grape polyphenols like myricetin, quercetin, kaempferol and nar- ingenin are medium potent ligands in the ⁇ M range. The oak polyphenol ellagic acid, however, was identified as high potent PPAR-gamma ligands with IC50s of 5.7xlO ⁇ 7 M. The binding potencies of the most abundant wine phenols were determined and listed (Table 5) .
  • Ellagitannins are extracted form the oak barrels and oak supplements during wine production and undergo an acid hydrolysis. They can also be extracted from the woody grape seeds and are converted during fermentation. Ellagic acid, which is also present in pomegranate in high amounts, was identified as strong PPAR-gamma binder. The antidiabetic effects of pomegranate are well known, but ellagic acid was not identified as PPAR-gamma ligand till now. Ellagitannins and ellagic acid are the most potent ligands for the PPAR-gamma receptor in wine; they are mainly derived from grape seeds and oak wood.
  • Red wine shows remarkable PPAR-gamma binding affinity up to an equivalent concentration of 500 ⁇ mol rosiglitazone / L.
  • Grape derived polyphenols have only a medium potency in the ⁇ M range, but oak derived compounds could be identified as strong PPAR- gamma ligands with IC50 values comparable with rosiglitazone, the synthetic compound for treatment of Metabolic Syndrome.
  • El- lagic acid was first reported as strong PPAR-gamma binder with an IC50 of 5.7xlO ⁇ 7 M and is therefore a potent compound for treatment of vascular diseases, inflammatory diseases, Metabolic Syndrome and insulin resistance due to PPAR-gamma pathway activity.
  • Recent findings of PPAR-gamma in platelets leads to the hypothesis, that such wine compounds can be responsible for the beneficial health effects of moderate wine consumption.

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur un composé comprenant une fraction d'acide ellagique, tel que l'acide ellagique lui-même, des ellagitannins et des glycosides d'acide ellagique - ainsi que sur des extraits végétaux comprenant ceux-ci, pour le traitement ou la prévention du syndrome métabolique ou de la résistance à l'insuline non diabétique.
PCT/AT2009/000200 2008-05-15 2009-05-15 Composés pour le traitement du syndrome métabolique et de la résistance à l'insuline WO2009137859A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09745281A EP2303252A1 (fr) 2008-05-15 2009-05-15 Composés pour le traitement du syndrome métabolique et de la résistance à l'insuline

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT7812008 2008-05-15
ATA781/2008 2008-05-15

Publications (1)

Publication Number Publication Date
WO2009137859A1 true WO2009137859A1 (fr) 2009-11-19

Family

ID=41008924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2009/000200 WO2009137859A1 (fr) 2008-05-15 2009-05-15 Composés pour le traitement du syndrome métabolique et de la résistance à l'insuline

Country Status (2)

Country Link
EP (1) EP2303252A1 (fr)
WO (1) WO2009137859A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071438A1 (fr) * 2012-11-08 2014-05-15 Cellarouge Pty Ltd Polyphénols modifiés et compositions de polyphénols modifiés
KR101615026B1 (ko) 2014-09-01 2016-04-22 순천대학교 산학협력단 시링산 또는 이의 염을 유효성분으로 포함하는 비만 또는 지질관련 대사성 질환의 예방 또는 치료용 조성물
JP2020510678A (ja) * 2017-03-08 2020-04-09 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ 対象におけるマイトファジーを改善するための方法
JP2020514338A (ja) * 2017-03-08 2020-05-21 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ 対象におけるマイトファジーを改善するための方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1312374A1 (fr) 2000-08-01 2003-05-21 Oryza Oil & Fat Chemical Co., Ltd Inhibiteurs d'absorption de sucre et leur procede de production
US20030236300A1 (en) 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
EP1481669A1 (fr) 2003-05-30 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Utilisation des polyhydroxy phenols et des polyphenols pour la modulation de l'activité de p-selectin
WO2006022502A1 (fr) 2004-08-23 2006-03-02 Neurogenex Co., Ltd. Composes presentant une structure diphenylique destines au traitement de maladies immunitaires
WO2006029483A1 (fr) 2004-09-14 2006-03-23 Ajinomoto Omnichem S.A. Polyphenols phosphoryles utilises comme agents de couleur stable
WO2006069385A2 (fr) 2004-12-22 2006-06-29 Renaissance Herbs, Inc. Compositions pharmaceutiques, therapeutiques et dietetiques derivees de lagerstroemia speciosa l.
WO2007038768A2 (fr) 2005-09-28 2007-04-05 The Regents Of The University Of California Procede pour abaisser la pression sanguine chez des individus pre-hypertendus et/ou des individus souffrant du syndrome metabolique
DE102006058243A1 (de) * 2006-12-11 2008-06-12 Hps Treuhand Gmbh Steuerberatungsgesellschaft Naturstoffgemisch zur Vorbeugung und Behandlung chronischer Krankheiten
WO2009031023A2 (fr) * 2007-09-07 2009-03-12 Probelte Pharma, S.A. « extraits de grenade, produits nutritionnels les contenant et leurs utilisations »

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236300A1 (en) 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
EP1312374A1 (fr) 2000-08-01 2003-05-21 Oryza Oil & Fat Chemical Co., Ltd Inhibiteurs d'absorption de sucre et leur procede de production
EP1481669A1 (fr) 2003-05-30 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. Utilisation des polyhydroxy phenols et des polyphenols pour la modulation de l'activité de p-selectin
WO2006022502A1 (fr) 2004-08-23 2006-03-02 Neurogenex Co., Ltd. Composes presentant une structure diphenylique destines au traitement de maladies immunitaires
WO2006029483A1 (fr) 2004-09-14 2006-03-23 Ajinomoto Omnichem S.A. Polyphenols phosphoryles utilises comme agents de couleur stable
WO2006069385A2 (fr) 2004-12-22 2006-06-29 Renaissance Herbs, Inc. Compositions pharmaceutiques, therapeutiques et dietetiques derivees de lagerstroemia speciosa l.
WO2007038768A2 (fr) 2005-09-28 2007-04-05 The Regents Of The University Of California Procede pour abaisser la pression sanguine chez des individus pre-hypertendus et/ou des individus souffrant du syndrome metabolique
DE102006058243A1 (de) * 2006-12-11 2008-06-12 Hps Treuhand Gmbh Steuerberatungsgesellschaft Naturstoffgemisch zur Vorbeugung und Behandlung chronischer Krankheiten
WO2009031023A2 (fr) * 2007-09-07 2009-03-12 Probelte Pharma, S.A. « extraits de grenade, produits nutritionnels les contenant et leurs utilisations »

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEERAM ET AL., SEPARATION AND PURIFICATION TECHNOLOGY, vol. 41, 2005, pages 49 - 55
SEERAM N ET AL: "Rapid large scale purification of ellagitannins from pomegranate husk, a by-product of the commercial juice industry", SEPARATION AND PURIFICATION TECHNOLOGY, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 41, no. 1, 1 January 2005 (2005-01-01), pages 49 - 55, XP004608865, ISSN: 1383-5866 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071438A1 (fr) * 2012-11-08 2014-05-15 Cellarouge Pty Ltd Polyphénols modifiés et compositions de polyphénols modifiés
KR101615026B1 (ko) 2014-09-01 2016-04-22 순천대학교 산학협력단 시링산 또는 이의 염을 유효성분으로 포함하는 비만 또는 지질관련 대사성 질환의 예방 또는 치료용 조성물
JP2020510678A (ja) * 2017-03-08 2020-04-09 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ 対象におけるマイトファジーを改善するための方法
JP2020514338A (ja) * 2017-03-08 2020-05-21 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ 対象におけるマイトファジーを改善するための方法

Also Published As

Publication number Publication date
EP2303252A1 (fr) 2011-04-06

Similar Documents

Publication Publication Date Title
Chuda et al. Mumefural, citric acid derivative improving blood fluidity from fruit-juice concentrate of Japanese apricot (Prunus mume Sieb. et Zucc)
US9376369B2 (en) Anti-cholesterolemic compounds and methods of use
Oliveira et al. Topical anti-inflammatory activity of yacon leaf extracts
JP5788065B2 (ja) リベス種から誘導可能な新たな生物活性アルカロイドおよびアルカロイド画分
US8362090B2 (en) Methods and related compositions using specific flavonoids and indanes to reduce weight and inhibit lipase, α-amylase and α-glucosidase activity in mammals
Wang et al. Vomifoliol 9-O-α-arabinofuranosyl (1→ 6)-β-D-glucopyranoside from the leaves of Diospyros Kaki stimulates the glucose uptake in HepG2 and 3T3-L1 cells
AU2008323968B2 (en) Extract of fraxinus excelsior seeds and therapeutic applications therefor
JP5004153B2 (ja) アディポネクチン産生促進剤
US20110268824A1 (en) Composition for preventing or treating artherosclerosis
Lv et al. Dihydrochalcone-derived polyphenols from tea crab apple (Malus hupehensis) and their inhibitory effects on α-glucosidase in vitro
EP2303252A1 (fr) Composés pour le traitement du syndrome métabolique et de la résistance à l'insuline
Sharp et al. Inhibitory effects of Cissus quadrangularis L. derived components on lipase, amylase and α-glucosidase activity in vitro
WO2010100933A1 (fr) Agent anti-obésité et agent d'amélioration du diabète
JP6157041B2 (ja) ＰＰＡＲγ活性化剤、抗肥満剤及び抗糖尿病剤
TWI432420B (zh) A compound isolated from the monascus, a process for its preparation and use
Buda et al. Cardioprotective effects of cultivated black chokeberries (Aronia spp.): Traditional uses, phytochemistry and therapeutic effects
JP2006008523A (ja) 生理活性フェノール性化合物およびそれを含有してなる食品
Yang et al. Houttuynia cordata extract improves physical endurance performance by regulating endothelial production of nitric oxide
Niewiadomska et al. Effects of L. peel extract supplementation on body weight, cardiac function, and haematological and biochemical parameters in an animal model of metabolic syndrome
US8921417B2 (en) Method of treating dyslipidemia using naturally occurring diterpene
WO2007084383A9 (fr) Méthode et composition pour le traitement de la maladie de parkinson
Pasheva et al. Effects of mulberry heartwood extract on genes related to lipid metabolism
Premprasert Anti-inflammatory Constituents from Croton stellatopilosusLeaves
Oku et al. DEVELOPMENT OF AN IN VIVO BIOASSAY METHOD FOR PRIMARY PREVENTIVE SUBSTANCES OF THE METABOLIC SYNDROME–EFFECT OF KINGINKA‐CHA

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09745281

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009745281

Country of ref document: EP